Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 9/2006

01-09-2006 | Original Paper

Reactivation of Hepatitis B Virus in Rheumatologic Patients Receiving Immunosuppressive Agents

Authors: Feng-Chiao Tsai, Song-Chou Hsieh, Ding-Shinn Chen, Jin-Chuan Sheu, Ding-Shinn Chen

Published in: Digestive Diseases and Sciences | Issue 9/2006

Login to get access

Excerpt

Reactivation of hepatitis B virus (HBV) replication in patients receiving cytotoxic or immunosuppressive therapy is a well-recognized complication [1]. The reactivation is characterized by an elevation of serum HBV-DNA levels and abnormal liver biochemistry tests, with a wide variety of clinical manifestations, ranging from mild, transient raised levels of serum aminotransferase to fulminant hepatitis [2]. The mechanism of liver injury in HBV reactivation is still not fully understood. It has been suggested that immunosuppressive agents result in increased viral replication. Following withdrawal of the agents, the function of the immune system is restored and immune-mediated destruction of hepatocytes ensues [3‐5]. In addition, glucocorticoids [6, 7] and doxorubicin [8] might directly stimulate HBV replication in vitro, and there is a specific glucocorticoid-response element in the HBV genome [7]. …
Literature
1.
Perrillo RP (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009–1022PubMedCrossRef
2.
Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 78:2210–2215PubMedCrossRef
3.
Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447–449PubMed
4.
Hanson RG, Peters MG, Hoofnagle JH (1986) Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 6:173–179PubMedCrossRef
5.
Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM (2000) Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 32:604–609PubMedCrossRef
6.
Chou CK, Wang LH, Lin HM, Chi CW (1992) Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 16:13–18PubMedCrossRef
7.
Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83:1627–1631PubMedCrossRef
8.
Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY, Chen PJ, Cheng AL (2004) Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 24:3035–3040PubMed
9.
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188PubMed
10.
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307PubMedCrossRef
11.
Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999) Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81:69–74PubMedCrossRef
12.
Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553–561PubMedCrossRef
13.
Duhart BTJr., Honaker MR, Shokouh-Amiri MH, Riely CA, Vera SR, Taylor SL, Al-jedai AH, Gaber AO (2003) Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transpl Infect Dis 5:126–131PubMedCrossRef
14.
Locasciulli A, Bacigalupo A, Van Lint MT, et al. (1990) Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases. Bone Marrow Transplant 6:25–29PubMed
15.
Seth P, Alrajhi AA, Kagevi I, Chaudhary MA, Colcol E, Sahovic E, Aljurf M, Gyger M (2002) Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 30:189–194PubMedCrossRef
16.
Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R (2002) Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100:391–396PubMedCrossRef
17.
Gane E, Pilmore H (2002) Management of chronic viral hepatitis before and after renal transplantation. Transplantation 74:427–437PubMedCrossRef
18.
Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, Jones EA, Seeff LB (1986) A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double–blind, placebo-controlled trial. Ann Intern Med 104:12–17PubMed
19.
Lam KC, Lai CL, Trepo C, Wu PC (1981) Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 304:380–386PubMedCrossRef
20.
Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320–1328PubMedCrossRef
21.
Chi ZC, Ma SZ (2003) Rheumatologic manifestations of hepatic diseases. Hepatobil Pancreat Dis Int 2:32–37
22.
Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, Mizushima Y (1999) Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 28:273–281PubMedCrossRef
23.
Ahern MJ, Smith MD, Roberts-Thomson PJ (1998) Methotrexate hepatotoxicity: What is the evidence? Inflamm Res 47:148–151PubMedCrossRef
24.
Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M (2005) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25:472–489PubMedCrossRef
25.
26.
Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742–1749PubMedCrossRef
27.
Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927–934PubMedCrossRef
28.
Liu CJ, Lai MY, Lee PH, Chou NK, Chu SH, Chen PJ, Kao JH, Jen YM, Chen DS (2001) Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. J Gastroenterol Hepatol 16:1001–1008PubMedCrossRef
29.
30.
Liaw YF, Chien RN (1999) Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B. J Gastroenterol Hepatol 14:804–806PubMedCrossRef
31.
Perrillo RP, Regenstein FG, Peters MG, DeSchryver-Kecskemeti K, Bodicky CJ, Campbell CR, Kuhns MC (1988) Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med 109:95–100PubMed
32.
Tupasi TE, Co VM, Clarin MS, Alesna ET, Divinagracia EM, Mangubat NV (2002) Randomized, double-blind, placebo-controlled trial of oromucosal low-dose interferon following prednisone withdrawal for chronic hepatitis B infection in Filipino patients. Int J Infect Dis 6:37–41PubMedCrossRef
33.
Liaw YF (1997) Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol 12:S346–S353PubMedCrossRef
34.
Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS (1983) Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 84:216–219PubMed
35.
Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W (2005) Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV Core antigen: low risk of HBV reactivation. Transplantation 79:1631–1633PubMedCrossRef
36.
Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311PubMedCrossRef
37.
Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R (2002) High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99:2324–2330PubMedCrossRef
38.
Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ (2004) High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11:55–59PubMedCrossRef
39.
Vento S, Cainelli F, Longhi MS (2002) Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 3:333–340PubMedCrossRef
40.
Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ (2001) Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65:473–477PubMedCrossRef
Metadata
Title
Reactivation of Hepatitis B Virus in Rheumatologic Patients Receiving Immunosuppressive Agents
Authors
Feng-Chiao Tsai
Song-Chou Hsieh
Ding-Shinn Chen
Jin-Chuan Sheu
Ding-Shinn Chen
Publication date
01-09-2006
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9074-8

Other articles of this Issue 9/2006

Digestive Diseases and Sciences 9/2006 Go to the issue

Original Paper

Clinical Response Is Associated with Elevated Plasma Interleukin-1 Receptor Antagonist During Selective Granulocyte and Monocyte Apheresis in Patients with Ulcerative Colitis

Original Paper

Confirmation and Prevention of Intestinal Barrier Dysfunction and Bacterial Translocation Caused by Methotrexate

Original Paper

Chondrosarcomatous Differentiation in Diffuse-Type Gastric Carcinoma

Original Paper

The Effect of Melatonin on TNBS-Induced Colitis

Original Paper

Helicobacter pylori Infection Is the Major Risk Factor for Gastric Inflammation in the Cardia

Original Paper

Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients with Gastresophageal Reflux Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits